John W. Smither - 04 Sep 2026 Form 4 Insider Report for NewAmsterdam Pharma Co N.V. (NAMS)

Reporting relationship: Director
Issuer ticker: NAMS
Reported as of: 04 Sep 2026
Net transaction value: -$40,512
SEC form: 4
Accepted by SEC: 09 Sep 2026, 16:30:03 UTC
Prior SEC filing: 04 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Michael Marino as Attorney-in-Fact for John W. Smither

Key filing fact

John W. Smither filed Form 4 for NewAmsterdam Pharma Co N.V. (NAMS) on 09 Sep 2026.

Key facts

This page summarizes John W. Smither's Form 4 filing for NewAmsterdam Pharma Co N.V. (NAMS).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 09 Sep 2026, 16:30.

Change

Previous filing in this sequence was filed on 04 Aug 2026.
Current net transaction value: -$40,512.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001559583 Primary reporting owner

Smither John W

Relationship: Director
Address: C/O NEWAMSTERDAM PHARMA COMPANY N.V., GOOIMEER 2-35, NAARDEN, NETHERLANDS
Signature: /s/ Michael Marino as Attorney-in-Fact for John W. Smither
Signature date: 09 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NAMS transaction

Ordinary Shares

Sale

Transaction value: $40,512
Shares: -1,600
Change %: -15%
Price: $25.32
Shares after: 8,760
Date: 04 Sep 2026
Ownership: Direct
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Reported transaction reflects a sale of ordinary shares to generate proceeds to satisfy the Reporting Person's tax obligations in connection with the prior vesting of restricted stock units.

Footnote F2

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.24 to $25.37 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.

Footnote F3

Includes 8,040 ordinary shares subject to restricted stock unit awards that remain subject to vesting.